XNAS
MURA
Market cap19mUSD
Apr 09, Last price
1.12USD
1D
2.75%
1Q
-69.32%
IPO
-70.53%
Name
Mural Oncology PLC
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-129m
L-38.05%
CFO
-129m
L-33.82%
Profile
Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was incorporated in 2017 and is based in Dublin, Ireland. As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY |
|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | |
| Income | ||||
Revenues | ||||
Cost of revenue | 138,262 | 194,638 | 196,686 | |
Unusual Expense (Income) | ||||
NOPBT | (138,262) | (194,638) | (196,686) | |
NOPBT Margin | ||||
Operating Taxes | 12,160 | 4,884 | ||
Tax Rate | ||||
NOPAT | (138,262) | (206,798) | (201,570) | |
Net income | (128,514) -38.05% | (207,447) 3.71% | (200,030) 14.02% | |
Dividends | ||||
Dividend yield | ||||
Proceeds from repurchase of equity | 196 | |||
BB yield | -0.36% | |||
| Debt | ||||
Debt current | 5,560 | 12,196 | 5,844 | |
Long-term debt | 10,484 | 23,920 | 32,928 | |
Deferred revenue | ||||
Other long-term liabilities | 235 | 304 | ||
Net debt | (128,341) | (234,994) | 58,158 | |
| Cash flow | ||||
Cash from operating activities | (128,545) | (194,249) | (168,588) | |
CAPEX | (92) | (3,452) | (5,511) | |
Cash from investing activities | (25,330) | (3,452) | (5,511) | |
Cash from financing activities | 196 | 468,811 | 174,099 | |
FCF | (128,610) | (255,287) | (196,954) | |
| Balance | ||||
Cash | 144,385 | 270,852 | (19,386) | |
Long term investments | 258 | |||
Excess cash | 144,385 | 271,110 | ||
Stockholders' equity | (159,200) | (30,690) | (21,656) | |
Invested Capital | 307,959 | 315,614 | 19,690 | |
ROIC | ||||
ROCE | 10,004.37% | |||
| EV | ||||
Common stock shares outstanding | 16,955 | 16,690 | 16,688 | |
Price | 3.22 -45.61% | 5.92 | ||
Market cap | 54,594 -44.75% | 98,803 | ||
EV | (73,747) | (136,191) | ||
EBITDA | (134,750) | (192,071) | (195,146) | |
EV/EBITDA | 0.55 | 0.71 | ||
Interest | ||||
Interest/NOPBT | ||||